# A Mechanistic Framework for in Silico Optimization of Neuroblastoma Chemo-Immunotherapy

Preprint · Kate Brockman, Brian Colburn, Joseph Garza, Yidong Liao, B. Veena S. N. Rao

- Archive id: arxiv:2511.05527
- Published: 2025-10-28
- arXiv: https://arxiv.org/abs/2511.05527
- Citations: 0
- Source URL: https://arxiv.org/abs/2511.05527
- PDF: https://arxiv.org/pdf/2511.05527
- Provenance: arxiv

## Abstract

A critical need exists for optimal therapeutic strategies for neuroblastoma, a prevalent and often fatal pediatric solid malignancy. To address the demand for quantitative models that can guide clinical decision-making, a novel mathematical framework was developed. Combination therapies involving immunotherapy, such as Interleukin-2 (IL-2), and chemotherapy, exemplified by Cyclophosphamide, have shown significant clinical potential by enhancing anti-tumor immune responses. In this study, a nonlinear system of coupled ordinary differential equations was formulated to mechanistically describe the interactions among tumor cells, natural killer (NK) cells, and cytotoxic T lymphocytes (CTLs). The pharmacodynamic effects of both IL-2 and Cyclophosphamide on these key immune populations were explicitly incorporated, allowing for the simulation of tumor dynamics across distinct patient risk profiles. The resulting computational framework provides a robust platform for the \\textit{\\textbf{in silico}} \\textbf{optimization} of therapeutic regimens, presenting a quantitative pathway toward the improvement of clinical outcomes for patients with neuroblastoma.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

Topics: [Cancer Immunotherapy](https://space-kitty.com/topics/cancer-immunotherapy)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.